Commercialization strategy for an intravenous hemostatic nanotechnology for bleeding management

Active Grant Awarded

Award ID
SB1HL184353
Recipient
Awarding agency
Obligated
$499,999

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 18% complete
Place of performance
Cleveland, OH 44106, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, National Heart Lung and Blood Institute, awarded Haima Therapeutics LLC $499,999 on September 17, 2026, under Cardiovascular Diseases Research (CFDA 93.837) through grant SB1HL184353. The grant is titled as a commercialization strategy for Synthoplate (SP), a platelet-inspired hemostatic nanoparticle that Haima is developing for intravenous bleeding management. The source describes SP as able to mimic and amplify the hemostatic mechanisms of natural platelets, without type matching, and as suited to large-scale manufacturing, sterilization, long shelf life, and portability. Phase I of the SBIR work demonstrated platelet-mimetic hemostatic activity in several ex vivo assays and mitigated bleeding in a TCP mouse hemorrhage model. The ultimate completion date is August 31, 2027, and the place of performance is Cleveland, Ohio 44106.

Description

Abstract
Millions of people experience life-threatening bleeding annually due to traumatic injury, surgeries, childbirth, and various bleeding disorders and diseases (e.g., thrombocytopenia). If not controlled, bleeding can cause significant downstream morbidities, such as organ dysfunction and infection, and even mortality. In fact, uncontrolled bleeding leads to nearly half a million deaths globally each year. Current bleeding management consist of a multifactorial therapeutic approach, including donor-derived blood transfusion, coagulation factors, and antifibrinolytic agents. Blood products are extremely limited in availability, increase risks of infection, and cause immune reactions. Coagulation factors (e.g., rfviia, FG concentrate, and 4F-PCC) are prohibitively expensive and are typically only used for patients with certain factor deficiencies. Antifibrinolytics (e.g., TXA) are inexpensive and can reduce blood loss by maintaining fibrin stability but have limited effectiveness due to not facilitating hemostatic clot formation and growth. Therefore, there exists an unmet clinical need for widely-applicable and cost-effective new approaches to facilitate hemostatic clot formation to reduce bleeding. To this end, haima therapeutics is developing synthoplate (SP), an innovative platelet-inspired hemostatic nanoparticle, that can mimic and amplify the primary hemostatic mechanisms of natural platelets, does not need type matching, and can allow large-scale manufacturing, sterilization, long shelf-life and easy portability. Haima envisions that SP will become a 'stand-alone' as well as 'adjunctive' treatment of active bleeding in many different clinical scenarios. In phase I of this sbir, SP demonstrated platelet-mimetic hemostatic ability in a variety of EX vivo hemostatic assays as well as the ability to mitigate bleeding in a TCP mouse hemorrhage model. In phase II, SP demonstrated the ability reduce bleeding in a more clinically relevant model of TCP in rabbits, recovered hemostatic function in TCP patient samples using several EX vivo biomarker assays, and demonstrated acceptable safety and PK profile in healthy and TCP rabbits. Furthermore, safety and efficacy have been demonstrated across numerous additional in vivo preclinical bleeding models, including tail transection models in mice with VON willebrand disease (VWD) and on anti-platelet therapy, liver laceration trauma/surgery models in rats, kidney incision trauma models after dilutional coagulopathy in rabbits, and polytrauma hemorrhage models in rabbits, highlighting SP's broad applicability in mitigating hemorrhage across many potential clinical indications. Therefore, the major objectives of this sbir commercialization readiness pilot (CRP) proposal are to support the development of a robust clinical and regulatory strategy for expeditious FDA approval (aim 1) and of a pricing and reimbursement strategy for the SP product in the initial and subsequent clinical indications (aim 2). The insights and plans generated under this proposal are critical to support partnering with a biotechnology company and/or additional venture capital investment to progress the SP technology into later-stage clinical development and commercialization.

Quick answers

Who received award SB1HL184353?

SB1HL184353 was awarded to Haima Therapeutics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 17, 2026.

How much is award SB1HL184353 worth?

$499,999 has been obligated on SB1HL184353.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award